ANJESOの薬剤に関する洞察と市場予測：2032年

ANJESO（メロキシカム）注射剤は、独自の長時間作用型の優先的COX-2阻害剤であり、シクロオキシゲナーゼ2型経路（COX-2）の阻害とそれに続くプロスタグランジン生合成の減少に関連した鎮痛、抗炎症、解熱作用を有します。ANJESO（メロキシカム）注射剤は、2020年2月に米国FDAにより、中等度から重度の疼痛を単独または非NSAID系鎮痛剤との併用で管理する成人患者を対象に承認されました。鎮痛効果の発現が遅いため、ANJESO単独での使用は、迅速な鎮痛効果の発現が必要な場合には推奨されません。

メロキシカムは、COX-2を優先的に阻害する長時間作用型の非ステロイド性抗炎症薬で、抗炎症作用、鎮痛作用、解熱作用を有し、これらの作用は、シクロオキシゲナーゼ（COX）の阻害とそれに続くプロスタグランジン生合成の減少に関連しています。ベーリンガーインゲルハイムは、1990年代から経口薬としてメロキシカム（MOBIC）を販売しています。変形性関節症および関節リウマチの症状の治療に使用されます。

当レポートでは、米国におけるANJESO市場について調査し、市場の概要とともに、2023年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 急性疼痛におけるANJESOの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• 規制上のマイルストーン
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 ANJESO市場評価

• 急性疼痛におけるANJESOの市場展望
• 米国の分析
  • 米国における急性疼痛治療薬ANJESOの市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

• 参考文献
• レポート調査手法

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: ANJESO, Clinical Trial Description, 2023
• Table 2: ANJESO, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: ANJESO Market Size in the US, in USD million (2019-2032)

List of Figures

• Figure 1: ANJESO Market Size in the United States, USD million (2019-2032)

"ANJESO Drug Insight and Market Forecast - 2032" report provides comprehensive insights about ANJESO for acute pain in the United States. A detailed picture of the ANJESO for acute pain in the United States for the study period 2019 -2032 is provided in this report along with a detailed description of the ANJESO for acute pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ANJESO market forecast analysis for acute pain in the US, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in acute pain.

Drug Summary:

ANJESO (meloxicam) injection is a proprietary, long-acting, preferential COX-2 inhibitor with analgesic, anti-inflammatory, and antipyretic activities related to inhibiting cyclooxygenase type 2 pathway (COX-2) and subsequent reduction in prostaglandin biosynthesis. ANJESO (meloxicam) injection was approved by the US FDA in February 2020 for adults to manage moderate-to-severe pain alone or in combination with non-NSAID analgesics. Because of the delayed onset of analgesia, ANJESO alone is not recommended for use when a rapid onset of analgesia is required.

Meloxicam is a long-acting NSAID with preferential COX-2 inhibition that possesses anti-inflammatory, analgesic, and antipyretic activities, which are related to the inhibition of cyclooxygenase (COX) and subsequent reduction in prostaglandin biosynthesis. Boehringer Ingelheim Pharmaceuticals have marketed (MOBIC) meloxicam as an oral agent since the 1990s. It is used for the treatment of symptoms of osteoarthritis and rheumatoid arthritis.

Dosage and administration

The recommended dose of ANJESO is 30 mg once daily, administered by IV bolus injection over 15 seconds.

Mechanism of action

Meloxicam has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of meloxicam, like other NSAIDs, is not completely understood but involves the inhibition of cyclooxygenase (COX-1 and COX-2). Meloxicam is a potent inhibitor of prostaglandin synthesis in vitro. Meloxicam concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin, inducing pain in animal models. Prostaglandins are mediators of inflammation.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the ANJESO description, mechanism of action, dosage and administration, research and development activities in acute pain.
• Elaborated details on ANJESO regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ANJESO research and development activities in acute pain across the United States.
• The report also covers the patents information with expiry timeline around ANJESO.
• The report contains forecasted sales of ANJESO for acute pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for acute pain.
• The report also features the SWOT analysis with analyst views for ANJESO in acute pain.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ANJESO Analytical Perspective by DelveInsight

In-depth ANJESO Market Assessment

This report provides a detailed market assessment of ANJESO for acute pain in the United States. This segment of the report provides forecasted sales data from 2023 to 2032.

ANJESO Clinical Assessment

The report provides the clinical trials information of ANJESO for acute pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for acute pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ANJESO dominance.
• Other emerging products for acute pain are expected to give tough market competition to ANJESO and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ANJESO in acute pain.
• Our in-depth analysis of the forecasted sales data of ANJESO from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ANJESO in acute pain.

Key Questions:

• What is the product type, route of administration and mechanism of action of ANJESO?
• What is the clinical trial status of the study related to ANJESO in acute pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ANJESO development?
• What are the key designations that have been granted to ANJESO for acute pain?
• What is the forecasted market scenario of ANJESO for acute pain?
• What are the forecasted sales of ANJESO in the United States?
• What are the other emerging products available and how are these giving competition to ANJESO for acute pain?
• Which are the late-stage emerging therapies under development for the treatment of acute pain?

Table of Contents

1. Report Introduction

2. ANJESO Overview in Acute pain

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestone
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. ANJESO Market Assessment

• 5.1. Market Outlook of ANJESO in Acute pain
• 5.2. The United States Analysis
  • 5.2.1. Market Size of ANJESO in the United States for Acute pain

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options